Illimis Therapeutics

Recent Finacing

Series B

Recent Raise

$41.8M

Illimis Therapeutics develops Gas6-mediated Anti-Inflammatory Adaptor (GAIA) platform therapies for CNS and immune disorders, advancing ILM01 for Alzheimer's toward preclinical IND and pursuing pharma co-development and academic collaborations.

Founded 2021

Seoul-t'ukpyolsi, South Korea

11-50

Private

illimistx.com

Highlights

Focus Areas

Biopharma

Biotechnology

Health Care

Pharmaceutical

Therapeutics

Recent Investors

Financials

$41.8M

Total Raised

1

Funding round

18

Investors

Team

Upgrade to view the team

See the team members at Illimis Therapeutics.